Sobi holds Capital Markets Seminar

The program for today's Capital Markets Seminar includes a company overview by
CEO Geoffrey McDonough,
a financial update by CFO Lars Sandström and a presentation of the phase III
projects in neonatology (Kiobrina®, an enzyme replacement therapy to prevent
growth restriction in preterm infants), and in hemophilia (long acting
recombinant Factor VIII FC and Factor IX FC for hemophilia A and B). All
presentations are streamed live atwww.sobi.com.

The purpose of the seminar is to provide insight to Sobi's operations and late-
stage development projects. No other long-term financial goals or guidance for
2012 other than described in this press release will be provided. Given the
adjusted timeline for the hemophilia projects as a result of the new guidelines
from the European Medicines Agency, the previous long-term financial targets are
no longer valid.

In his company overview, CEO Geoffrey McDonough will focus on Sobi's objectives
to achieve positive cash flow and profitability, and to commercialize its
pipeline of proprietary innovative medicines for rare diseases. The company will
prioritize greater operational efficiency, growth of the product portfolio in
existing and in selected new geographies, and the execution of the research
projects according to plan.

The commercial business will be presented in three lines:
  * ReFacto® with net revenues of SEK 608 M, including royalty, and a gross
    margin above 60%.
  * Core Products (Kineret®, Orfadin®, Ammonaps®, Ammonul® and Ruconest®) with
    net revenues of SEK 803 M and a gross margin of approximately 60%.
  * Specialty Distribution Products with revenues of SEK 459 M and a gross
    margin below 50%.

Product area                    |Revenues |Growth|Gross margin, %
--------------------------------+---------+------+---------------
ReFacto®                        |      608|   34%|           >60%
                                |         |      |
Core Products                   |      803|    6%|           ~60%
                                |         |      |
Specialty Distribution Portfolio|      459|    8%|            <40
--------------------------------+---------+------+---------------

Revenues are rolling 12 months as of 30 September 2011 in reported exchange
rates, adjusted for discontinued products. Growth figures are based on YTD 9
months 2011, adjusted for currency and discontinued products.

CFO Lars Sandström will comment on the development of revenues, gross margin and
working capital from 2009 to September 2011:
  * Adjusted for changes in exchange rates and discontinued products, total
    revenues during this period increased by an annual average of approximately
    7%, despite price reductions imposed by the authorities in many European
    countries.
  * The high growth rate for ReFacto® in 2011 is due to exceptionally high
    production as a result of the delivery of validation batches in the amount
    of approximately SEK 40 M.
  * The gross margin from 2009 to September 2011 was negatively impacted by
    approximately SEK 120 M or
    6 percentage points relating to currency effects due to the strengthening of
    the Swedish krona.
  * The gross margin was also negatively affected by an additional amount of
    approximately SEK 120 M or 6 percentage points by various short-term
    effects, in particular the transfer of Kineret® production and the building
    up of stock in the amount of approximately SEK 500 M in preparation for the
    tech transfer, as well as by the production of validation batches for
    ReFacto®.
  * Conversion of the Kineret® substance into finished product has been largely
    completed in 2011 and this will have a positive impact on working capital as
    stock levels will gradually fall in 2012 and 2013. The goal is to be back at
    normal stock levels in line with 2009 by 2013.

Write-down of balance sheet items
As reported in the interim report for Q3 2011, a number of balance sheet items
will be written down in Q4 2011. The write-downs will amount to an estimated SEK
300-320 M and the items to be written down are listed in the table below. The
write-downs will have a limited impact on cash flow.

Asset           |Product   |Amount, SEKm |
----------------+----------+-------------+--------------------------------------
                |          |             |Revaluation of validation batches for
Inventory       |Kineret®  |        70-80|Kineret® in order to value inventory
                |          |             |at commercial value.
                |          |             |
                |          |             |Reduced but stabilized revenues
                |Kepivance®|           30|require write-down of inventory bought
                |          |             |in 2008.
                |          |             |
Trade receivable|          |           20|Write-down of overdue receivables.
                |          |             |
                |          |             |Write-down of Leptin project
Intangibles     |          |          130|outlicensed to Astra Zeneca due to
                |          |             |reduced probability of commercial
                |          |             |success.
                |          |             |
                |          |             |Valuation of liability related to
Real estate     |          |        50-60|previous premises.  Write-down of
                |          |             |assets related to new premises.
----------------+----------+-------------+--------------------------------------
Total           |          |      300-320|
----------------+----------+-------------+--------------------------------------


Transfer of Kineret® production
As previously announced, the transfer of Kineret® production from manufacturer
Amgen Inc. in the US to a contract manufacturer in Europe has been delayed due
to technical issues. The costs relating to the transfer during the first nine
months of 2011 amounted to SEK 30 M. Final process validation runs are scheduled
to be completed in the first quarter of 2012. Sobi has maintained the option to
purchase additional supply from Amgen should a further delay occur, and will
make this decision by the second quarter of 2012.

Phase III projects progressing according to plan
Kiobrina
Kiobrina® is a recombinant human bile salt stimulated lipase (rhBSSL) being
developed by Sobi as an enzyme replacement therapy to improve growth in preterm
infants who receive pasteurized breast milk or infant formula. Data from this
project is expected during 2013 and Sobi expects to commercialize Kiobrina
during 2015. Kiobrina is a unique project with a potential to reach
approximately 100 000 patients based on the ongoing study.

Kiobrina, Phase III study
--------------------------------------
Placebo-controlled, double blind study

4 weeks treatment

430 patients, <32 weeks

11 countries, 70 sites
--------------------------------------


Hemophilia
Sobi's  and Biogen Idec's rFIXFc and  rFVIIIFc hemophilia projects are advancing
according to plan with recruitment of patients in both phase III studies (B-LONG
and  A-LONG, respectively). Data from both  studies are expected to be delivered
during  the second half of 2012. The pediatric  studies are expected to start in
the  first half of 2012. Following the initiation of the pediatric studies, Sobi
expects  the  total  development  program,  including  regulatory  review, to be
completed  within three  to four  years i.e.  2016 would be  the first year with
significant  revenues. The total market for hemophilia within Sobi's territories
is growing and is currently USD 3.4 billion.

Hemophilia projects                                       rFIXFc        rFVIIIFc
--------------------------------------------------------------------------------
Phase III studies                                         B-LONG          A-LONG

No. of patients                                              105             150

Start date                                                Dec-09          Nov-10

Phase III data                                           H2 2012         H2 2012

Start of pediatric studies in previously treated         H1 2012         H1 2012
patients

Orphan drug designation                           USA and Europe USA and  Europe
--------------------------------------------------------------------------------


No. of patients required in the European studies rFIXFc rFVIIIFc
----------------------------------------------------------------
Previously treated patients >12 years                20       50

Previously treated patients 6- <12 år                10       25

Previously treated patients <6 years                 10       25
----------------------------------------------------------------

Ref. EMA (European Medicines Agency)


For further information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations (temp)
Tel.: +46 8 697 21 88


Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 60 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ
Stockholm. More information is available atwww.sobi.com.

The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 29 November 2011 at 1.15 p.m. CET.

In order to utilize the 'Safe Harbor' provisions of the United States Private
Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum is providing
the following cautionary statement. This presentation contains forward-looking
statements with respect to the financial condition, results of operations and
businesses of Swedish Orphan Biovitrum. By their nature, forward-looking
statements and forecasts involve risk and uncertainty because they relate to
events and depend on circumstances that will occur in the future. There are a
number of factors that could cause actual results and developments to differ
materially from that expressed or implied by these forward-looking statements.
These factors include, among other things, the loss or expiration of patents,
marketing exclusivity or trade marks; exchange rate fluctuations; the risk that
R&D will not yield new products that achieve commercial success; the impact of
competition, price controls and price reductions; taxation risks; the risk of
substantial product liability claims; the impact of any failure by third parties
to supply materials or services; the risk of delay to new product launches; the
difficulties of obtaining and maintaining governmental approvals for products;
the risk of failure to observe ongoing regulatory oversight; the risk that new
products do not perform as we expect; and the risk of environmental liabilities.